CervoMed Future Growth
Future criteria checks 2/6
CervoMed's earnings are forecast to decline at 52.1% per annum while its annual revenue is expected to grow at 39.1% per year. EPS is expected to decline by 41% per annum. Return on equity is forecast to be -60.1% in 3 years.
Key information
-52.1%
Earnings growth rate
-41.0%
EPS growth rate
| Biotechs earnings growth | 24.5% |
| Revenue growth rate | 39.1% |
| Future return on equity | -60.1% |
| Analyst coverage | Low |
| Last updated | 10 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -39 | -49 | -47 | 2 |
| 12/31/2025 | 7 | -26 | -32 | -30 | 2 |
| 12/31/2024 | 8 | -12 | -12 | -11 | 2 |
| 12/31/2023 | 7 | -2 | -7 | -7 | N/A |
| 9/30/2023 | 5 | -1 | -6 | -6 | N/A |
| 3/31/2023 | 1 | -6 | -3 | -3 | N/A |
| 12/31/2022 | N/A | -6 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRVO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRVO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRVO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRVO's revenue (39.1% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: CRVO's revenue (39.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRVO is forecast to be unprofitable in 3 years.